Please wait while the formulary information is being retrieved.
FLUPHENAZINE DECANOATE (fluphenazine decanoate)
- Schizophrenia
- Psychotic disorder
25 mg/mL injection solution
- Inject 1 milliliter (25 mg) by subcutaneous route every 2 weeks
Psychotic disorder
- Inject 1 milliliter (25 mg) by intramuscular route once weekly
- Inject 1 milliliter (25 mg) by subcutaneous route once weekly
- Inject 1 milliliter (25 mg) by intramuscular route every 4 weeks
- Inject 1 milliliter (25 mg) by subcutaneous route every 4 weeks
- Inject 1 milliliter (25 mg) by intramuscular route every 2 weeks
- Inject 1 milliliter (25 mg) by subcutaneous route every 2 weeks
- Inject 1 milliliter (25 mg) by intramuscular route every 3 weeks
- Inject 1 milliliter (25 mg) by subcutaneous route every 3 weeks
- Inject 2 milliliters (50 mg) by subcutaneous route every 3 weeks
- Inject 2 milliliters (50 mg) by intramuscular route every 3 weeks
- Inject 2 milliliters (50 mg) by subcutaneous route every 2 weeks
- Inject 2 milliliters (50 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (50 mg) by subcutaneous route every 4 weeks
- Inject 2 milliliters (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (50 mg) by subcutaneous route once weekly
- Inject 2 milliliters (50 mg) by intramuscular route once weekly
- Inject 0.5 milliliter (12.5 mg) by subcutaneous route once weekly
- Inject 0.5 milliliter (12.5 mg) by intramuscular route once weekly
- Inject 0.5 milliliter (12.5 mg) by intramuscular route every 4 weeks
- Inject 0.5 milliliter (12.5 mg) by subcutaneous route every 4 weeks
- Inject 0.5 milliliter (12.5 mg) by intramuscular route every 2 weeks
- Inject 0.5 milliliter (12.5 mg) by subcutaneous route every 2 weeks
- Inject 0.5 milliliter (12.5 mg) by intramuscular route every 3 weeks
- Inject 0.5 milliliter (12.5 mg) by subcutaneous route every 3 weeks
Schizophrenia
- Inject 1 milliliter (25 mg) by intramuscular route every 4 weeks
- Inject 1 milliliter (25 mg) by subcutaneous route every 4 weeks
- Inject 0.5 milliliter (12.5 mg) by intramuscular route every 4 weeks
- Inject 0.5 milliliter (12.5 mg) by subcutaneous route every 4 weeks
- metoclopramide HCl
- Metozolv Odt
- Orap
- pimozide
- Reglan
Contraindicated
- Apokyn
- apomorphine
- cabergoline
- carbidopa-levodopa
- carbidopa-levodopa-entacapone
- Comtan
- entacapone
- lithium carbonate
- lithium citrate
- Lithobid
- Mirapex
- Mirapex Er
- pramipexole
- Requip
- Requip Xl
- ropinirole
- Sinemet
- Sinemet Cr
- Stalevo 100
- Stalevo 125
- Stalevo 150
- Stalevo 200
- Stalevo 50
- Stalevo 75
Severe
Moderate
- Alagesic Lq
- amobarbital
- Amytal
- Aplenzin
- Ascomp With Codeine
- Belladonna-phenobarbital
- Bupap
- Buproban
- bupropion HBr
- bupropion HCl
- butabarbital
- Butalbital Compound W/codeine
- Butalbital Compound-codeine
- butalbital-acetaminop-caf-cod
- butalbital-acetaminophen
- butalbital-acetaminophen-caff
- butalbital-aspirin-caffeine
- Butisol
- Capacet
- codeine-butalbital-ASA-caff
- Donnatal
- Esgic
- Fioricet
- Fioricet With Codeine
- Fiorinal
- Fiorinal-codeine #3
- Forfivo Xl
- Luminal
- Margesic
- Marten-tab
- Mysoline
- Nembutal Sodium
- pentobarbital sodium
- phenobarb-hyoscy-atropine-scop
- phenobarbital
- phenobarbital sodium
- primidone
- secobarbital sodium
- Seconal Sodium
- Tencon
- Wellbutrin
- Wellbutrin Sr
- Wellbutrin Xl
- Zebutal
- Zyban
- Coma
- Neuroleptic malignant syndrome
- Stupor
Contraindicated
- Acute myocardial infarction
- Benign prostatic hyperplasia with lower urinary tract sx
- Carcinoma of breast
- Cardiac arrhythmia
- Congenital long QT syndrome
- Disease of liver
- Extrapyramidal disease
- Glaucoma
- Hypocalcemia
- Hypokalemia
- Hypomagnesemia
- Metabolic syndrome X
- Myocardial ischemia
- Organophos insecticide poisoning
- Pregnancy
- Prolonged QT interval
- Senile dementia
- Tardive dyskinesia
- Torsades de pointes
- Urinary retention
Severe
Moderate
- Alcoholism
- Anemia
- Angina
- Bradycardia
- Chronic disease of respiratory system
- Chronic heart failure
- Hyperglycemia
- Hyperprolactinemia
- Leukopenia
- Neutropenic disorder
- Obesity
- Orthostatic hypotension
- Parkinsonism
- Predisposition to aspiration
- Seizure disorder
- Thrombocytopenic disorder
- Weight gain
FLUPHENAZINE DECANOATE (fluphenazine decanoate)
- Schizophrenia
- Psychotic disorder
- Akathisia
- Blurred vision
- Extrapyramidal disease
- Hypotension
- Pigmentary retinopathy
- Syncope
- Tardive dyskinesia
- Constipation
- Decreased sweating
- Dizziness
- Drowsy
- Nasal congestion
- Orthostatic hypotension
- Sialorrhea
- Xerostomia
More Frequent
Severe
Less Severe
- Contact dermatitis
- Dysuria
- Skin photosensitivity
- Abnormal sexual function
- Breast engorgement
- Galactorrhea not associated with childbirth
- Irregular menstrual periods
- Mastalgia
- Weight gain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Agranulocytosis
- Heat stroke
- Hypothermia
- Leukopenia
- Melanosis
- Neuroleptic malignant syndrome
- Neutropenic disorder
- Obstructive hyperbilirubinemia
- Priapism
- Prolonged QT interval
- Seizure disorder
- Torsades de pointes
- Visual changes
Less Severe
- Fever
- Photophobia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Fluphenazine
Safety and effectiveness in children have not been established.
- 1 Day – 13 Years
- Safety and effectiveness in children have not been established.
Fluphenazine
- Severity Level:
D
- Additional Notes: No fda category; neonate complications(resp,gi,cns) w/use in 3rd trimester
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Fluphenazine
Low amnt excr w/similar drug chlorpromazine, resulting in infant drowsiness
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Low amnt excr w/similar drug chlorpromazine, resulting in infant drowsiness |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Fluphenazine
Neuro/Psych-Increased risk of tardive dyskinesia. CNS effects; sedation, cognitive impairment and inc fall risk. Avoid, except in FDA-approved indications. Inc risk of stroke, cognitive decline, and death when used w/senile dementia. Endocrine-May exacerbate or cause SIADH or hyponatremia. Cardiovascular-May cause orthostatic hypotension at higher doses. Gastrointestinal-May cause or worsen constipation. Genitourinary-Avoid in patients w/urinary retention.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | Y | N | Y |
BEERS: Y HEDIS: Y STOPP: Y
No Known Risk
None
- There may be a slightly increased risk of serious, possibly fatal side effects (such as heart failure, fast/irregular heartbeat, pneumonia) when this medication is used by older adults with dementia. This medication is not approved for the treatment of dementia-related behavior problems. Discuss the risks and benefits of this medication, as well as other effective and possibly safer treatments for dementia-related behavior problems, with the doctor.
| Psychotic disorder | |
| F06.0 | Psychotic disorder with hallucinations due to known physiological condition |
| F06.2 | Psychotic disorder with delusions due to known physiological condition |
| F23 | Brief psychotic disorder |
| F24 | Shared psychotic disorder |
| Schizophrenia | |
| F20 | Schizophrenia |
| F20.0 | Paranoid schizophrenia |
| F20.1 | Disorganized schizophrenia |
| F20.2 | Catatonic schizophrenia |
| F20.3 | Undifferentiated schizophrenia |
| F20.5 | Residual schizophrenia |
| F20.8 | Other schizophrenia |
| F20.81 | Schizophreniform disorder |
| F20.89 | Other schizophrenia |
| F20.9 | Schizophrenia, unspecified |
| 0-9 | A-Z |
|---|---|
| F06.0 | Psychotic disorder with hallucinations due to known physiological condition |
| F06.2 | Psychotic disorder with delusions due to known physiological condition |
| F20 | Schizophrenia |
| F20.0 | Paranoid schizophrenia |
| F20.1 | Disorganized schizophrenia |
| F20.2 | Catatonic schizophrenia |
| F20.3 | Undifferentiated schizophrenia |
| F20.5 | Residual schizophrenia |
| F20.8 | Other schizophrenia |
| F20.81 | Schizophreniform disorder |
| F20.89 | Other schizophrenia |
| F20.9 | Schizophrenia, unspecified |
| F23 | Brief psychotic disorder |
| F24 | Shared psychotic disorder |
Formulary Reference Tool